NPI registry status
Active
2026 NPPES data Endocrinology, Diabetes & Metabolism Physician NPI 1467624064 D.O.
Verify on CMS → Theofanis Mitsinikos, D.O.
Endocrinology, Diabetes & Metabolism Physician in Stony Brook, New York.
This profile is drawn from the federal National Provider Identifier Registry (CMS NPPES), which lists more than 7 million U.S. healthcare providers - including 7,871 in Endocrinology, Diabetes & Metabolism Physician, and covers specialty classification, practice address, and Medicare Part D prescribing data when reported. According to CMS, every field reflects the provider's official federal registration, see our methodology.
Federal data, no proprietary rating.
We show these CMS records as-is - no composite score, no star rating, no editorial opinion layered on top.
Prescribing volume
6K
Medicare Part D claims · 801 beneficiaries · Endocrinology, Diabetes & Metabolism Physician avg: 3K
Generic prescribing
42%
generic claims · 54% brand-name · higher generic rates reduce patient out-of-pocket costs
MIPS score
69.6/100
▼ 14 pts below national avg 83.5 · Mid-tier
Industry payments
$26.3K
203 payments · CMS Open Payments (Sunshine Act)
Source: CMS Medicare Part D Prescriber Public Use File, 2023
What the federal data shows
Theofanis Mitsinikos, D.O. reported a CMS MIPS final score of 69.6/100 - below the 83.5 national average - and filed 5,939 Medicare Part D claims in 2023.
- 69.6/100
- MIPS score · -14 vs avg
- 6K
- Part D claims, 2023
- 42%
- generic prescribing
- Likely
- board-certified (heuristic)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) - no proprietary rating or editorial opinion is applied.
Theofanis Mitsinikos, D.O.'s MIPS score vs every measured U.S. clinician
CMS Merit-based Incentive Payment System (MIPS) final score, 2023, the federal quality measure. Clinicians whose score CMS assigned without scoring any category are excluded.
70 ≥ 8th percentile 8% of 454,083 measured providers are in lower value bands
Each bar is a band; taller bars hold more measured providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
The percentile is a conservative whole-score-point band: it counts only measured clinicians in lower score bands. A CMS MIPS metric is not a recommendation or a clinical-quality rating by PlainDoctor. See methodology § corpus placement.
Source CMS Merit-based Incentive Payment System (MIPS) · 2023
Where Theofanis Mitsinikos, D.O. sits
This provider among endocrinology, diabetes & metabolism physician peers
Across the 2,341 endocrinology, diabetes & metabolism physician providers who report both Medicare Part D prescribing and a MIPS quality score, Theofanis Mitsinikos, D.O. writes more Part D claims than 87% of them and scores higher on MIPS quality than 10% - placing this provider in the high-volume, lower-quality quadrant. Volume reflects patient-panel size and specialty, not quality; the two axes are independent.
Each dot is one endocrinology, diabetes & metabolism physician peer from a representative sample of 60; the gold marker is Theofanis Mitsinikos, D.O.. Source: CMS Medicare Part D Prescriber data and the CMS Merit-based Incentive Payment System, 2023.
✓
Board certification likely (heuristic, not verified)
Theofanis Mitsinikos, D.O. practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting - signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about Theofanis Mitsinikos, D.O.?
Below national averagePrimary specialty
Endocrinology, Diabetes & Metabolism Physician
Medicare Part D claims
5,939 125% vs specialty avg
MIPS final score
69.6/100 13.9 pts vs avg
Specialty distribution in New York
How Endocrinology, Diabetes & Metabolism Physician compares to other specialties among New York providers
Medicare quality performance, MIPS
Theofanis Mitsinikos, D.O.'s 2023 MIPS final score plotted against the Endocrinology, Diabetes & Metabolism Physician national average
- MIPS Final Score
- 69.6/100
- vs 83.5 national avg · 2023 performance year
How MIPS and board certification work
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
Theofanis Mitsinikos, D.O. appears in the CMS NPPES registry as an Endocrinology, Diabetes & Metabolism Physician provider holding D.O. credentials at 2500 NESCONSET HWY, Stony Brook, NY, 11790, with a listed phone of (631) 751-2400. NPI 1467624064 was issued on 03/24/2008.
Medicare Part D records for calendar year 2023 show 5,939 prescription claims written by this provider, covering 801 Medicare beneficiaries and totaling roughly $4.2 million in drug spend, split 54% brand-name and 42% generic by claim count. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 69.6/100 for the 2023 performance year (Quality 69.4, Cost 39.6), compared with the 83.5 average among clinicians with a measured score.
Endocrinology, Diabetes & Metabolism Physician is a mid-sized specialty nationwide, with 7,871 enrolled providers across 54 states and an average of 2,639 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline.
Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist, always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1467624064 |
|---|---|
| Specialty | Endocrinology, Diabetes & Metabolism Physician |
| Credentials | D.O. |
| Gender | Male |
| NPI Issued | 03/24/2008 |
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
69.6443
Final Score
Measured-score avg: 83.5
69.4362
Quality
39.566
Cost
Reporting: Individual
Industry payments received (2024) - CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for Theofanis Mitsinikos, D.O.. Source: openpaymentsdata.cms.gov.
Total received
$26.3K
Largest payer
Mannkind Corporation
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias, they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
License & disciplinary context - New York NYSBPMC 2023 annual report
Aggregate state board data only, NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~100K New York medical licensees in 2023 - they are NOT specific to Theofanis Mitsinikos, D.O.. To verify Theofanis Mitsinikos, D.O.'s current license status, search the NYSBPMC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
312
Total board actions, New York 2023
Across 302 cases
3.12
Actions per 1,000 licensees
New York statewide rate
probation
Most common action type
89 cases
NYSBPMC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the New York disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Brand-heavy
Theofanis Mitsinikos, D.O. - brand share 54.0%
Endocrinology, Diabetes & Metabolism Physician average
54% brand-name claims vs 42% generic, on 5,939 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
5,939
Total Claims
$4.2M
Total Drug Cost
801
Medicare Beneficiaries
Prescribing Breakdown
- 30-Day Fills
- 16,365
- Total Day Supply
- 489,775
- Brand vs Generic
- 54% brand / 42% generic
- Brand Drug Cost
- $4.0M
- Generic Drug Cost
- $201K
Patient Demographics
- Average Patient Age
- 74.5 years
- Avg HCC Risk Score
- 1.28
- Gender Split
- 62% female / 38% male
- Age Distribution
- <65: 45, 65-74: 341, 75-84: 352, 85+: 63
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What Theofanis Mitsinikos, D.O. prescribes most
Top Medicare Part D drugs by claim count, 2023
- Synthroid
Synthroid
726 claims
- Levothyroxine Sodium
Levothyroxine Sodium
650 claims
- Metformin Hcl Er
Metformin Hcl Er
461 claims
- Trulicity
Trulicity
304 claims
- Farxiga 286
Farxiga
286 claims
- Rosuvastatin Calcium 205
Rosuvastatin Calcium
205 claims
- Atorvastatin Calcium 199
Atorvastatin Calcium
199 claims
- Ozempic 192
Ozempic
192 claims
| Drug | Claims |
|---|---|
| Synthroid Levothyroxine Sodium | 726 |
| Levothyroxine Sodium | 650 |
| Metformin Hcl Er Metformin Hcl | 461 |
| Trulicity Dulaglutide | 304 |
| Farxiga Dapagliflozin Propanediol | 286 |
| Rosuvastatin Calcium | 205 |
| Atorvastatin Calcium | 199 |
| Ozempic Semaglutide | 192 |
| Bydureon Bcise Exenatide Microspheres | 148 |
| Metformin Hcl | 145 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
More Endocrinology, Diabetes & Metabolism Physician in NY →
All providers in New York →
Compare specialties →
Endocrinology, Diabetes & Metabolism Physician Overview
How Theofanis Mitsinikos, D.O. fits within the Endocrinology, Diabetes & Metabolism Physician landscape nationally.
7,871
Endocrinology, Diabetes & Metabolism Physician Providers in US
54
States with Endocrinology, Diabetes & Metabolism Physician
2,639
Avg Claims per Provider
Theofanis Mitsinikos, D.O.'s 5,939 claims are above the specialty average of 2,639.
Nearby Endocrinology, Diabetes & Metabolism Physician Providers in New York
Other clinicians with the same primary specialty enrolled in New York, drawn from the same CMS NPPES roster as Mitsinikos.
One of 797 Endocrinology, Diabetes & Metabolism Physician providers enrolled in New York, 5 are shown here.
Dr. Zinoviy Abelev
MD
Long Island City, NY
Dr. Jill Abelseth
M.D.
Albany, NY
Dr. Sherley Abraham
M.D.
New York, NY
Dr. Jennifer Abrams
DO
Brooklyn, NY
Dr. Naim Abrar
M.D.
Riverhead, NY
Compare Endocrinology, Diabetes & Metabolism Physician nationally: see state-by-state distribution →
Before you book an appointment
Use this federal record as your verification checklist, not as a recommendation.
- Confirm the NPI record is current in the official CMS registry, providers update their own NPPES details, and moves can lag. Verify this NPI
- Check the active license and any disciplinary history with the New York medical board, federal registration is not a license check. Credential verification guide
- Weigh a second option: compare this provider with a nearby Endocrinology, Diabetes & Metabolism Physician peer on Medicare volume and prescribing patterns. Compare providers
Medicare Part D and MIPS figures describe practice patterns in federal programs only, they are not quality ratings, and PlainDoctor does not rate, rank, or recommend providers.
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
How to Find a Doctor
Step-by-step guide to choosing a provider
Verify Credentials
Check NPI, board certification & license status
Medical Specialties Explained
Who treats what and how specialties differ
Understanding Medicare Claims Data
What prescribing data reveals about a provider
In-Network vs Out-of-Network
How insurance networks affect your costs
Telehealth Guide
Virtual care options and coverage in 2026
Explore New York
Frequently Asked Questions
What is Theofanis Mitsinikos, D.O.'s specialty? ▼
Theofanis Mitsinikos, D.O. specializes in Endocrinology, Diabetes & Metabolism Physician and practices in Stony Brook, New York. Credentials: D.O..
How much does Theofanis Mitsinikos, D.O. prescribe under Medicare Part D? ▼
In 2023, Theofanis Mitsinikos, D.O. wrote 5,939 Medicare Part D claims totaling $4.2M in drug costs for 801 beneficiaries.
What is Theofanis Mitsinikos, D.O.'s Medicare quality score? ▼
Theofanis Mitsinikos, D.O. has a CMS MIPS Final Score of 69.6/100 (Quality: 69.4, Cost: 39.6). The average MIPS Final Score across the 454,083 clinicians with at least one published category score is 83.5; clinicians whose score CMS assigned without scoring any category are excluded from that average. Source: CMS Merit-based Incentive Payment System (MIPS) 2023.
Where is Theofanis Mitsinikos, D.O. located? ▼
Theofanis Mitsinikos, D.O. is located at 2500 NESCONSET HWY, Stony Brook, NY, 11790. Phone: (631) 751-2400.
What is Theofanis Mitsinikos, D.O.'s NPI number? ▼
Theofanis Mitsinikos, D.O.'s National Provider Identifier (NPI) is 1467624064, issued on 03/24/2008.
Does Theofanis Mitsinikos, D.O. prescribe more brand-name or generic drugs? ▼
Theofanis Mitsinikos, D.O.'s prescribing is 54% brand-name and 42% generic drugs by claim count, with $4.0M in brand drug costs.
How many Endocrinology, Diabetes & Metabolism Physician providers are there in the US? ▼
There are 7,871 Endocrinology, Diabetes & Metabolism Physician providers across 54 states in the US. The average Endocrinology, Diabetes & Metabolism Physician provider writes 2,639 Medicare Part D claims per year.
What drugs does Theofanis Mitsinikos, D.O. prescribe most often? ▼
Based on 2023 Medicare Part D data, Theofanis Mitsinikos, D.O.'s most frequently prescribed drugs include Synthroid, Levothyroxine Sodium, Metformin Hcl Er. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does Theofanis Mitsinikos, D.O. accept Medicare? ▼
Theofanis Mitsinikos, D.O. appears in CMS Medicare data with 5,939 Part D claims and 801 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify Theofanis Mitsinikos, D.O.'s credentials? ▼
Theofanis Mitsinikos, D.O.'s NPI is 1467624064 with credentials D.O.. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.
Data Sources
View source datasets and methodology notes
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) - 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology
Every figure on PlainDoctor is rendered directly from the federal CMS NPPES registry, Medicare Part D, MIPS, and Open Payments records, no number is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.